Adalimumab (Humira) may alter production of tumor necrosis factor-alpha in rheumatoid arthritis patients, returning TNFα levels almost to normal. A study looking at antibodies against the drug in psoriatic arthritis found no clear evidence of an effect.
(VIDEO) Researchers in Norway used data from an observational study of patients with swollen joints to see how many with early signs of rheumatoid arthritis recovered without any treatment at all, and how quickly.
(VIDEO) With rising attention to anti-citrullinated protein antibodies (ACPA) in RA classification, what is the current significance of rheumatoid factor? Rheumatologist Josef Smolen tells how he and others at the Medical University of Vienna addressed the question.
(VIDEO) Ultrasound can trump the DAS28 in judging the equation between rheumatoid arthritis symptoms and joint signs when making treatment decisions. James Dale MD describes his study reported at the American College of Rheumatology meeting.
For rheumatologists in the US, defining outcomes is the "Wild West," says Jeffrey Curtis MD in this podcast. Listen as he describes a new $1 million grant intended to rationalize treatment decisions through data sharing and the use of electronic devices to gather patient-centered input.
(ACR Pediatrics 2014) How will the hundreds of new genetic biomarkers being found in rheumatology help us to untangle the web of complex diseases? In a brief podcast, a specialist in both rheumatology and genetics discusses recent and future progress.
More than a third of patients aren't taking DMARDs as guidelines unanimously recommend. Rheumatologist Richard Martin MD reveals insights from new research about why some patients resist the idea, and what you can do to help.